62 research outputs found
A Human Minor Histocompatibility Antigen Specific for B Cell Acute Lymphoblastic Leukemia
Human minor histocompatibility antigens (mHags) play an important role in the induction of cytotoxic T lymphocyte (CTL) reactivity against leukemia after human histocompatibility leukocyte antigen (HLA)-identical allogeneic bone marrow transplantation (BMT). As most mHags are not leukemia specific but are also expressed by normal tissues, antileukemia reactivity is often associated with life-threatening graft-versus-host disease (GVHD). Here, we describe a novel mHag, HB-1, that elicits donor-derived CTL reactivity in a B cell acute lymphoblastic leukemia (B-ALL) patient treated by HLA-matched BMT. We identified the gene encoding the antigenic peptide recognized by HB-1–specific CTLs. Interestingly, expression of the HB-1 gene was only observed in B-ALL cells and Epstein-Barr virus–transformed B cells. The HB-1 gene–encoded peptide EEKRGSLHVW is recognized by the CTL in association with HLA-B44. Further analysis reveals that a polymorphism in the HB-1 gene generates a single amino acid exchange from His to Tyr at position 8 within this peptide. This amino acid substitution is critical for recognition by HB-1–specific CTLs. The restricted expression of the polymorphic HB-1 Ag by B-ALL cells and the ability to generate HB-1–specific CTLs in vitro using peptide-loaded dendritic cells offer novel opportunities to specifically target the immune system against B-ALL without the risk of evoking GVHD
A Human Minor Histocompatibility Antigen Specific for B Cell Acute Lymphoblastic Leukemia
Mucin impedes cytotoxic effect of 5-FU against growth of human pancreatic cancer cells: overcoming cellular barriers for therapeutic gain
Mucins are high molecular weight glycoproteins expressed on the apical surface of normal epithelial cells. In cancer disease mucins are overexpressed on the entire cellular surface. Overexpression of MUC1 mucin in pancreatic tumours has been correlated with poor patient survival. Current chemotherapeutic approaches such as 5-fluorouracil (5-FU) has produced limited clinical success. In this study we investigated the role of mucin in cytotoxic drug treatment to determine whether the extracellular domain of mucin impedes cytotoxic drug action of 5-FU. Human pancreatic cancer cells revealed high and relatively moderate MUC1 levels for Capan-1 and HPAF-II, respectively, compared to MUC1 negative control (U-87 MG glioblastoma) that showed relatively non-specific anti-MUC1 uptake. Benzyl-α-GalNAc (O-glycosylation inhibitor) was used to reduce mucin on cell surfaces, and neuraminidase was used to hydrolyse sialic acid at the distal end of carbohydrate chains. Benzyl-α-GalNAc had no effect on cell morphology or proliferation at the concentrations employed. The inhibition of O-glycosylation resulted in significant 5-FU antiproliferative activity against Capan-1 and HPAF-II, but not against U-87 MG. However, the exposure of cells to neuraminidase failed to improve the cytotoxic action of 5-FU. Our experimental findings suggest that the overexpression of mucin produced by human pancreatic tumours might limit the effectiveness of chemotherapy
Differential cytostatic activity of monocyte-derived cytokines against human melanoma cells
Contains fulltext :
27176.PDF (publisher's version ) (Open Access
Clonal predominance of cytomegalovirus-specific CD8+ cytotoxic T-lymphocytes in bone marrow recipients
Contains fulltext :
23528___.PDF (publisher's version ) (Open Access
Lymphocyte function-associated antigen 1 dominates very late antigen 4 in binding of activated T cells to endothelium
Contains fulltext :
27160.PDF (publisher's version ) (Open Access
Regulation of integrin-mediated adhesion to laminin and collagen in human melanocytes and in non-metastatic and highly metastatic human melanoma cells
Contains fulltext :
27166.PDF (publisher's version ) (Open Access
Activation and expansion of tumor-infiltrating lymphocytes by anti-CD3 and anti-CD28 monoclonal antibodies
Item does not contain fulltex
Succes van infusie met lymfocyten als behandeling van leukemierecidief na allogene beenmergtransplantatie is afhankelijk van een laag percentage eigen lymfocyten
Contains fulltext :
23047___.PDF (publisher's version ) (Open Access
Recognition of a B cell leukemia-associated minor histocompatibility antigen by CTL
Contains fulltext :
27112___.PDF (publisher's version ) (Open Access
- …